Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma

Fig. 5

Changes in tumor volume over time after each treatment in (a) C3H mice implanted with MH-134 cells and (d) C57BL/6 mice implanted with RIL-175 cells. Tumor volumes at the end of each treatment in (b) C3H mice implanted with MH-134 cells and (e) C57BL/6 mice implanted with RIL-175 cells. Gross specimen of tumors at the end of each treatment in (c) C3H mice implanted with MH-134 cells and (f) C57BL/6 mice implanted with RIL-175 cells. The numbers of mice assigned to each treatment group are as follows: control (n = 8), sorafenib (n = 9), CKD-5 (n = 9), and CKD-5 plus sorafenib (n = 9) in C3H mice, control (n = 6), sorafenib (n = 7), CKD-5 (n = 7), and CKD-5 plus sorafenib (n = 7) in C57BL/6 mice. Combination therapy of CKD-5 with sorafenib significantly suppressed tumor growth more than either sorafenib or CKD-5 monotherapy

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us